| TA244 |
Chronic obstructive pulmonary disease - roflumilast (TA244) |
|
-
-
Roflumilast for the management of severe chronic obstructive pulmonary disease
NICE recommends roflumilast for people with severe COPD only if they are taking part in a research study (clinical trial) that is investigating using roflumilast at the same time as a bronchodilator (a type of inhaled drug).
Why has NICE said this?
NICE looks at how well treatments work, and also at how well they work in relation to how much they cost the NHS.
NICE recommended that roflumilast should be used only as part of a research study because at the moment there is not enough evidence about how well it works or about the best way to use it to recommend it for use in the NHS.
-
Other information
How this guidance was produced
Background information
- None found
This page was last updated: 23 January 2012
-
-
Guidance formats
-
Implementation tools and resources
See this guidance in practice
Patient
The summary of the key recommendations in the guidance written for patients, carers and those with little medical knowledge and may be used in local patient information leaflets.
Quick Reference Guide
The quick reference guide presents recommendations for health professionals
NICE Guidance
The published NICE clinical guidance, contains the recommendations for health professionals and NHS bodies.
Full Guidance
The published full clinical guidance for specialists with background, evidence, recommendations and methods used.
